Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | TNKS | O95271 | 6/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232626 | 0.80 | EPHX2 (0.62) | EPHX2CNR1CNR2ALDH1A1GAA | |
| SCHEMBL3294867 | 0.79 | P2RX7 (0.57) | P2RX7EPHX2CNR1CNR2POLB | |
| Trifluoroacetic Acid SCHEMBL2581954 | 0.77 | P2RX7 (0.44) | P2RX7TNKSTNKS2CYP2C9CYP2C19 | |
| SCHEMBL15534698 | 0.77 | P2RX7 (0.44) | P2RX7TNKSTNKS2CYP2C9CYP2C19 | |
| SCHEMBL20049209 | 0.76 | P2RX7 (0.48) | P2RX7TNKSTNKS2CYP2C9CYP2C19 | |
| SCHEMBL26101508 | 0.74 | SETDB1 (0.44) | P2RX7EPHX2 | |
| SCHEMBL26099823 | 0.74 | EPHX2 (0.51) | P2RX7EPHX2 | |
| SCHEMBL2575857 | 0.74 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL2575855 | 0.74 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL15534934 | 0.73 | P2RX7 (0.42) | P2RX7TNKSTNKS2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049478-B1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885EPHX2 1309/4885TNKS 2213/4885 |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885EPHX2 1309/4885TNKS 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.